(MPW) Medical Properties Trust - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58463J3041

Stock: Hospitals, Real Estate, Leasing, Acquisitions, Financing

Total Rating 43

Risk 52

Buy Signal 0.01

REIT - Healthcare Facilities » Health Care REITs
Age: 20.6y

Market Cap: 3,020m
Avg Trading Vol: 31.1M USD

ATR: 2.70%
Peers RS (IBD): 43.75

EPS (Earnings per Share)

EPS CAGR: -14.15%
EPS Trend: -57.4%

Last SUE: -0.04
Qual. Beats: 0

Revenue

Rev. CAGR: -13.89%
Rev. Trend: -10.4%

Last SUE: -0.05
Qual. Beats: 0

Dividends

Dividend Yield	6.66%
Yield on Cost 5y	2.24%
Yield CAGR 5y	-26.32%
Payout Consistency	92.7%
Payout Ratio	-

Risk 5d forecast
Volatility	30.3%
Relative Tail Risk	-12.9%

Reward TTM
Sharpe Ratio	0.48
Alpha	7.67

Character TTM
Beta	0.668
Beta Downside	0.954

Drawdowns 3y
Max DD	73.64%
CAGR/Max DD	-0.22

Description: MPW Medical Properties Trust January 13, 2026

Medical Properties Trust, Inc. (MPW) is a self-advised REIT founded in 2003 that specializes in acquiring, developing, and leasing hospital facilities on a net-lease basis. As of September 30 2025, the company owned 388 hospitals comprising roughly 39,000 licensed beds across nine countries on three continents, making it one of the largest global owners of hospital real estate.

Key operating metrics that investors watch include a funds-from-operations (FFO) yield of about 6.5 % and a weighted-average lease term of 10.5 years, which provides relatively stable cash flow. The REIT’s growth is closely tied to demographic aging trends and the increasing demand for healthcare infrastructure, while its financing model-leveraging sale-leaseback transactions-allows hospital operators to monetize real-estate assets for capital expenditures and technology upgrades. A recent strategic focus has been on expanding in high-margin markets such as Europe and Asia, where occupancy rates for specialty hospitals remain above 95 %.

For a deeper dive into MPW’s valuation dynamics and scenario analysis, you might find ValueRay’s interactive tools useful.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income: -707.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.01 > 1.0
NWC/Revenue: 48.38% < 20% (prev 48.70%; Δ -0.32% < -1%)
CFO/TA 0.01 > 3% & CFO 147.4m > Net Income -707.4m
Net Debt (9.37b) to EBITDA (699.1m): 13.40 < 3
Current Ratio: 1.43 > 1.5 & < 3
Outstanding Shares: last quarter (600.9m) vs 12m ago 0.11% < -2%
Gross Margin: 81.82% > 18% (prev 0.97%; Δ 8085 % > 0.5%)
Asset Turnover: 6.21% > 50% (prev 4.21%; Δ 2.00% > 0%)
Interest Coverage Ratio: 0.64 > 6 (EBITDA TTM 699.1m / Interest Expense TTM 705.9m)

Altman Z'' -0.90

A: 0.03 (Total Current Assets 1.52b - Total Current Liabilities 1.07b) / Total Assets 14.92b
B: -0.27 (Retained Earnings -4.10b / Total Assets 14.92b)
C: 0.03 (EBIT TTM 454.8m / Avg Total Assets 15.08b)
D: -0.38 (Book Value of Equity -3.94b / Total Liabilities 10.26b)
Altman-Z'' Score: -0.90 = CCC

Beneish M -3.19

DSRI: 0.88 (Receivables 1.12b/876.8m, Revenue 936.9m/641.3m)
GMI: 1.18 (GM 81.82% / 96.76%)
AQI: 0.16 (AQ_t 0.15 / AQ_t-1 0.90)
SGI: 1.46 (Revenue 936.9m / 641.3m)
TATA: -0.06 (NI -707.4m - CFO 147.4m) / TA 14.92b)
Beneish M-Score: -3.19 (Cap -4..+1) = AA

What is the price of MPW shares?

As of February 08, 2026, the stock is trading at USD 5.36 with a total of 4,729,148 shares traded.
Over the past week, the price has changed by +6.77%, over one month by +1.13%, over three months by +8.11% and over the past year by +17.04%.

Is MPW a buy, sell or hold?

Medical Properties Trust has received a consensus analysts rating of 2.73. Therefor, it is recommend to hold MPW.

StrongBuy: 0
Buy: 2
Hold: 5
Sell: 3
StrongSell: 1

What are the forecasts/targets for the MPW price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	5.2	-3.5%
Analysts Target Price	5.2	-3.5%
ValueRay Target Price	5.1	-5.6%

MPW Fundamental Data Overview February 04, 2026

P/E Forward = 6.6667
P/S = 2.9921
P/B = 0.6479
P/EG = 1.93
Revenue TTM = 936.9m USD
EBIT TTM = 454.8m USD
EBITDA TTM = 699.1m USD
Long Term Debt = 9.05b USD (from longTermDebt, last quarter)
Short Term Debt = 567.6m USD (from shortTermDebt, last quarter)
Debt = 9.76b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.37b USD (from netDebt column, last quarter)
Enterprise Value = 12.39b USD (3.02b + Debt 9.76b - CCE 396.6m)
Interest Coverage Ratio = 0.64 (Ebit TTM 454.8m / Interest Expense TTM 705.9m)
EV/FCF = 84.05x (Enterprise Value 12.39b / FCF TTM 147.4m)
FCF Yield = 1.19% (FCF TTM 147.4m / Enterprise Value 12.39b)
FCF Margin = 15.73% (FCF TTM 147.4m / Revenue TTM 936.9m)
Net Margin = -75.50% (Net Income TTM -707.4m / Revenue TTM 936.9m)
Gross Margin = 81.82% ((Revenue TTM 936.9m - Cost of Revenue TTM 170.4m) / Revenue TTM)
Gross Margin QoQ = 68.01% (prev 67.72%)
Tobins Q-Ratio = 0.83 (Enterprise Value 12.39b / Total Assets 14.92b)
Interest Expense / Debt = 2.51% (Interest Expense 245.5m / Debt 9.76b)
Taxrate = 21.0% (US default 21%)
NOPAT = 359.3m (EBIT 454.8m * (1 - 21.00%))
Current Ratio = 1.43 (Total Current Assets 1.52b / Total Current Liabilities 1.07b)
Debt / Equity = 2.10 (Debt 9.76b / totalStockholderEquity, last quarter 4.66b)
Debt / EBITDA = 13.40 (Net Debt 9.37b / EBITDA 699.1m)
Debt / FCF = 63.56 (Net Debt 9.37b / FCF TTM 147.4m)
Total Stockholder Equity = 4.77b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.69% (Net Income -707.4m / Total Assets 14.92b)
RoE = -14.83% (Net Income TTM -707.4m / Total Stockholder Equity 4.77b)
RoCE = 3.29% (EBIT 454.8m / Capital Employed (Equity 4.77b + L.T.Debt 9.05b))
RoIC = 2.54% (NOPAT 359.3m / Invested Capital 14.17b)
WACC = 3.49% (E(3.02b)/V(12.78b) * Re(8.37%) + D(9.76b)/V(12.78b) * Rd(2.51%) * (1-Tc(0.21)))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.16%
[DCF Debug] Terminal Value 83.44% ; FCFF base≈210.1m ; Y1≈163.9m ; Y5≈105.6m
Fair Price DCF = N/A (negative equity: EV 3.26b - Net Debt 9.37b = -6.11b; debt exceeds intrinsic value)
EPS Correlation: -57.37 | EPS CAGR: -14.15% | SUE: -0.04 | # QB: 0
Revenue Correlation: -10.37 | Revenue CAGR: -13.89% | SUE: -0.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.02 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.12 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+0.0% | Growth Revenue=+6.9%

Additional Sources for MPW Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle